Trastuzumab Deruxtecan in Patients With HER2 -Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial
National Cancer Center Hospital East · Tokyo National Hospital · +41 more institutions
Abstract
PURPOSE Trastuzumab deruxtecan (T-DXd) 5.4 and 6.4 mg/kg showed robust antitumor activity in multiple cancer indications; however, T-DXd 5.4 mg/kg has not been evaluated in patients with previously treated human epidermal growth factor receptor 2–mutant ( HER2m; defined as single-nucleotide variants and exon 20 insertions) metastatic non–small-cell lung cancer (mNSCLC). METHODS DESTINY-Lung02, a blinded, multicenter, phase II study, investigated T-DXd 5.4 mg/kg once every 3 weeks for the first time in previously treated (platinum-containing therapy) patients with HER2m mNSCLC and further assessed T-DXd 6.4 mg/kg once every 3 weeks in this population. The primary end point was confirmed objective response rate…
Citation impact
- FWCI
- 67.29
- Percentile
- 100%
- References
- 29
Authors
24Topics & keywords
- Medicine
- Internal medicine
- Trastuzumab
- Population
- Gastroenterology
- Clinical endpoint
- Lung cancer
- Phases of clinical research
- Good health and well-being
Funding
- AAmgen
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- SSanofi
- GSGilead Sciences
- SPSpectrum Pharmaceuticals
- CCelgene
- MMedpace
- GHGenomic Health
- MKMerck KGaA
- TPTaiho Pharmaceutical
- LLLes Laboratories Pierre Fabre
- BBeiGene
- YYuhan
- AMAzərbaycan Milli Elmlər Akademiyası
- SSeagen
- EEisai
- KHKyowa Hakko Kirin
- APAstellas Pharma
- OPOno Pharmaceutical
- GGenentech
- SSamsung
- CPChugai Pharmaceutical
- IIgnyta
- BYBayer Yakuhin
- AAAmgen Astellas Biopharma
- DSDaiichi Sankyo Europe